The relationship between uric acid levels and Huntington's disease progression

• Published in: Movement disorders Vol. 25; no. 2; pp. 224 - 228
• Main Authors: Auinger, Peggy, Kieburtz, Karl, Mcdermott, Michael P.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 30.01.2010; Wiley
• Subjects: Adult; Aged; Biological and medical sciences; Biomarkers - blood; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Disease Progression; Female; Humans; Huntington Disease - blood; Huntington Disease - diagnosis; Huntington Disease - physiopathology; Huntington's disease; Male; Medical sciences; Middle Aged; Movement; Neurology; Prognosis; progression; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; uric acid; Uric Acid - blood; Nervous system diseases; uric acid: progression; Central nervous system disease; Huntington disease; Degenerative disease; Uric acid; Huntington's disease; Genetic disease; Cerebral disorder; Extrapyramidal syndrome
• ISSN: 0885-3185; 1531-8257; 1531-8257
• DOI: 10.1002/mds.22907

Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society